Equities

Iconovo AB

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Iconovo AB

Actions
  • Price (SEK)1.12
  • Today's Change0.00 / 0.00%
  • Shares traded33.27k
  • 1 Year change-70.90%
  • Beta0.8185
Data delayed at least 15 minutes, as of Feb 11 2026 17:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Iconovo AB is a Sweden-based company, which offers inhalation solutions for pharmaceutical companies. Solutions are based on the Company’s device platforms and include formulation, analytical testing and documentation. Iconovo Ab develops products, which are a part of device family and include: ICOres, reservoir devices, ICOone, disposable unit-dose devices, ICOcap, capsule-based devices and ICOpre, pre-metered devices. Moreover, the Company offers programs, which include development of generic inhalation products, where the products are registered based on therapeutic equivalence; development of inhalation products based on a generic application programming interface (API) and new chemical entity (NCE); as well as phase I-II clinical trials using ICOone.

  • Revenue in SEK (TTM)1.59m
  • Net income in SEK-41.23m
  • Incorporated2013
  • Employees19.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Neola Medical AB0.00-10.99m57.84m8.00--0.7372-----0.1479-0.14790.001.010.00----0.00-13.81-15.62-14.65-16.86--5,384.30---6,523.935.61--0.00-------11.70--35.63--
Luxbright AB11.49m-19.25m62.08m12.00--2.31--5.40-0.1644-0.16440.09680.20670.27887.732.68---46.74-56.30-59.61-66.28-6.22-79.12-167.60-450.361.22-83.810.1076--26.5279.40-9.86------
Kontigo Care AB29.13m-2.07m62.54m10.00--1.2417.282.15-0.0589-0.05890.82621.430.4487--7.97---3.190.296-3.980.4064125.51129.99-7.120.4638----0.00---3.667.41-367.61--17.15--
Episurf Medical AB15.60m-62.70m69.52m26.00--0.6498--4.46-0.064-0.0640.01570.06450.1641--3.95577,777.80-65.44-45.67-74.89-50.07-----398.72-857.082.50--0.0844--23.5819.3919.83--6.68--
Redsense Medical AB (publ)30.67m302.00k74.00m4.00224.662.06125.212.410.020.021.862.180.76971.966.616,134,600.000.7578-14.280.8514-15.8661.4568.850.9846-32.794.69--0.00--12.8516.26107.58---53.01--
Scandinavian ChemoTech AB11.68m-8.70m75.92m1.00--13.19--6.50-0.3727-0.37270.50030.26530.7270.59172.661,946,333.00-54.15-92.70-83.07-131.4682.15104.65-74.49-866.060.861-5.610.00--132.6763.8534.96---59.68--
Observe Medical ASA15.64m-115.27m87.04m4.00--3.59--5.57-26.57-26.573.290.19090.11182.878.293,350,800.00-82.38-42.22-205.00-64.146.2430.17-737.14-327.970.1175-3.720.9572---33.85153.47-98.73---2.97--
BibbInstruments AB149.00k-13.30m88.81m4.00--2.08--596.05-0.3802-0.38020.00411.050.00382.062.7137,250.00-33.98-36.85-35.53-40.0630.8759.14-8,922.82-22,555.646.67--0.00-------15.85---1.52--
SyntheticMR AB (publ)57.05m-54.93m101.39m41.00--0.6871--1.78-0.9057-0.90570.94671.650.3678--0.87331,391,415.00-35.42-7.92-51.34-10.5110.4156.07-96.28-14.37---8.730.0450--2.473.20-241.50--7.37--
Arcoma AB132.94m4.35m107.03m31.0023.341.469.240.80510.32050.32059.875.131.452.9213.714,288,452.004.752.166.663.7540.4537.953.271.402.04--0.000.00-3.813.24336.0011.08-9.43--
Iconovo AB1.59m-41.23m107.71m19.00--0.4547--67.88-1.67-1.670.05372.460.0117--0.260863,475.20-30.39-28.39-33.14-31.51901.69159.24-2,598.41-295.86---138.020.0391---58.55-24.2210.36--22.28--
Immunovia AB (publ)785.00k-125.52m127.13m9.00------161.95-0.3569-0.35690.0024-0.0210.0156--0.26487,222.22-249.16-48.08-827.53-52.27-7,231.59-6,932.30-15,989.68-17,625.510.6282-3.001.68---40.8921.2075.26------
Scandinavian Real Heart AB0.00-38.87m137.96m12.00--0.8266-----16.17-16.170.0016.690.00----0.00-44.53-27.49-52.77-30.65-------12,518.77----0.0678------49.47--6.59--
Bioretec Oy-1.06tn-1.06tn141.91m57.00---------------------------57.56---77.31--70.90---128.20--------16.3221.07-21.78------
Scandinavian Medical Solutions A/S347.28m36.79k150.68m28.005,803.031.2812.170.43390.00070.00078.882.991.291.9411.19--0.01376.590.024611.6823.1224.880.01064.680.35241.140.4345--8.2842.38-99.67-64.34----
Ortivus AB75.91m-24.74m150.86m34.00------1.99-0.5583-0.55831.71-0.50621.186.7716.222,372,281.00-38.46-4.62-147.30-8.6534.7941.27-32.59-3.550.4719-4.011.72---4.369.60-36.49--65.37--
Data as of Feb 11 2026. Currency figures normalised to Iconovo AB's reporting currency: Swedish Krona SEK

Institutional shareholders

0.74%Per cent of shares held by top holders
HolderShares% Held
Fj�rde AP-fondenas of 30 Jun 2025392.75k0.74%
Cicero Fonder ABas of 30 Jan 20260.000.00%
Data from 30 Sep 2025 - 30 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.